What You Should Know:
- Pfizer announced it will acquire biotechnology company Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion. The proposed combination enhances Pfizer’s position as a leading company in Oncology.
Seagen’s medicines, late-stage development programs and pioneering expertise in Antibody-Drug Conjugates (ADCs) strongly complement Pfizer’s Oncology portfolio.
Seagen Background
Seagen is a pioneer in ADC technology, with
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
H1 Launches Advanced Diversity and Clinical Trial Performance Insights
What You Should Know:
- H1, the connecting force for global healthcare provider, clinical, science, and research information, today announced the availability of indication-level diversity insights in addition to institution, provider, and patient diversity data within its Trial Landscape solution.
- Additionally, H1 has successfully onboarded its first customer – a top 20 pharmaceutical company – onto the H1 Data Network, a new solution that aggregates sponsor-contributed site and
Read More
Drug Development: Allucent Expands Use of Medidata Clinical Cloud
What You Should Know:
- Medidata announced that Allucent, a contract research organization (CRO) bringing innovation to biopharma companies, is expanding the global use of Medidata’s Clinical Cloud to advance its end-to-end clinical trial operations offering.
- The agreement expands Allucent’s existing utilization of Medidata technologies. These include Rave EDC, eCOA, RTSM,
Read More
Clarapath Acquires AI-Powered Digital Pathology Platform Crosscope
What You Should Know:
- Clarapath, a robotics company aimed at catalyzing change in the way pathology laboratories process human and animal tissue acquires Mountain View, CA-based Crosscope. Financial details of the acquisition were not disclosed.
- Crosscope is a digital pathology company with a turnkey imaging solution providing best-in-class workflow tools and slide management along with artificial intelligence (AI) and machine learning (ML) technology to assist pathologists with better
Read More
C2i Genomics, Riken Genesis Expands AI-Powered Whole-Genome MRD Cancer Detection Across Japan
What You Should Know:
- C2i Genomics, a cancer intelligence company, today announced a collaboration with Riken Genesis Co., Ltd. (RG), a company specializing in providing the service of personalized medicine based on contract analysis of next-generation sequencing and exomes. The two companies have entered a collaboration agreement to bring MRD cancer monitoring to Japan for pharmaceutical and clinical research.
- Under this agreement, RG will work with C2i Genomics to commercialize
Read More
Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month
What You Should Know:
- Eli Lilly and Company today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month at participating retail pharmacies.
- The historic price cut makes it easier to access Lily insulin for Americans who may have difficulty navigating a complex healthcare system that may keep them from getting affordable
Read More
M&A: ArisGlobal to Acquire Amplexor Life Sciences
What You Should Know:
- ArisGlobal, the leading provider of life sciences software designed to automate core drug development functions, acquired Amplexor Life Sciences, a global provider of regulatory, quality, and safety software solutions. Financial details of the acquisition were not disclosed.
- This combined product ecosystem provides a new opportunity for life sciences companies, bringing together best-in-breed solutions to form a cohesive solution serving customers’
Read More
OpenText Partners with Bayer to Digitize B2B Operations
What You Should Know:
- Global tech anchor, OpenText™ announced its collaboration with healthcare and agricultural leader, Bayer, to simplify its digital operations.
- This partnership echoes the current trend which sees legacy companies adopting more robust digital solutions to elevate their businesses and free up time to focus on other priorities.
- Bayer has strategically chosen OpenTextTM Business Network Cloud Enterprise, which will be tapped for strategic B2B
Read More
Why Clinical Data Research Needs a Makeover in 2023
Clinical research is only as good and thorough as the data that’s available — and we need to do a better job of making that data accessible for researchers.
Unfortunately, the majority of clinical data is based on the same clinical sites and makes conclusions off a limited range of data points. Clinical trials often exclude minorities, rare disease subtypes and other underrepresented populations.
Changing the way we gather and share clinical data isn’t easy. Hospitals, biobanks and
Read More
Tempus, Pfizer Partner to Advance Oncology Therapeutic Development
What You Should Know:
- Today, the AI-powered genetic testing and precision medicine company Tempus announced that it has signed a significant strategic agreement with Pfizer to more precisely gather insights that will inform novel drug discovery and development in oncology.
- Through this collaboration, Pfizer has access to Tempus’ AI-enabled platform and its library of de-identified, multimodal data to uncover insights that will power therapeutic development in oncology.
-
Read More
